Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

Pharmacy Benefits Management Services

Menu
Menu
Quick Links
Veterans Crisis Line Badge
My healthevet badge
 

VA Center For Medication Safety (VA MedSAFE)

Archived Content

The content on this page is provided for reference purposes only.  This content has not been altered or updated since original date posted.  Links may not be active.

Safety Issue

Date of Release

Old Safety Information
TNF-a Blockers, including Simponi [golimumab], and Risk of Fungal Infections

05/27/2009

 FDA MedWatch Safety Alert
Propafenone HCL 225mg (Watson) and Variability in Active Ingredient Recall 03/30/2009 FDA Recall - Firm Press Release
Transdermal Patches Containing Metal and Risk of Burns 03/05/2009 FDA Public Health Advisory
Metoclopramide and Risk of Tardive Dyskinesia 02/26/2009 FDA News
Zonisamide (marketed as Zonegran, and generics) and Possible Metabolic Acidosis 02/23/2009 FDA Information for Healthcare Professionals
Duragesic Patch (50mcg/hr) and Cut in Drug Reservoir Recall 12/31/2008 Johnson and Johnson News
Antipsychotic Use and Increase Risk of Death in Patients with Dementia-Related Psychosis 6/16/2008 FDA Information for Healthcare Professionals
Tumor Necrosis Factor (TNF) Antagonists and the Development of Lymphomas and Other Cancers in Children and Young Adults (< 18 years) 6/4/2008 FDA Early Communication
Use of Abacavir or Didanosine and Higher Risk of Heart Attack 4/4/2008 National HIV/AIDS Program Commentary
Heparin Manufacturer Recalls 4/2/2008 B. Braun Internal Distribution Letter
Heparin Manufacturer Recalls 3/28/2008 FDA Firm Press Release - Covidien Voluntary recall of Heparin Pre-Filled Syringes
Use of Abacavir or Didanosine and Higher Risk of Heart Attack 3/27/2008 FDA Early Communication
Heparin Manufacturer Recalls 3/21/2008 FDA Firm Press Release for B.Braun Medical, Inc.
Etanercept and Tuberculosis and Infections 3/14/2008 Dear Healthcare Professional Letter (Amgen)
EPOGEN®/PROCRIT® and Aranesp® and Additional Trials Showing Increased Mortality and/or Tumor Progression 3/7/2008 Dear Healthcare Professional Letter (Amgen)
Myfortic® (mycophenolic acid) and Increased Risks of Pregnancy Loss and Congenital Malformations / Change from Pregnancy Category C to Pregnancy Category D 11/27/2007 Dear Healthcare Professional Letter (Novartis)
Varenicline (marketed as Chantix) and Suicidal Thoughts and Aggressive or Erratic Behavior 11/20/2007 FDA Early Communication
Varenicline (marketed as Chantix) and Suicidal Thoughts and Aggressive or Erratic Behavior 11/20/2007 FDA Patient Information Sheet
Rosiglitazone and Increased Risk of Myocardial Ischemia 11/19/2007 FDA Information for Healthcare Professionals
Sildenafil (marketed as Viagra and Revatio) Vardenafil (marketed as Levitra) Tadalafil (marketed as Cialis) and Hearing Loss 11/14/2007 FDA Information for Healthcare Professionals
Cefipime (marketed as Maxipime) and Increased Mortality 11/14/2007 FDA Early Communication
IV Haloperidol and Torsades de Pointe 9/17/2007 FDA MedWatch Summary
Ceftriaxone (Rocephin®) and Incompatibility with Calcium Products UPDATE 9/11/2007 FDA Alert
Ceftriaxone (Rocephin®) and Incompatibility with Calcium Products UPDATE 9/11/2007 Information for Healthcare Professionals (FDA)
Viracept (nelfinavir mesylate) and presence of ethyl methanesulfonate (EMS), a process-related impurity 9/10/2007 FDA Drug Safety Information
Entecavir (Baraclude®) and potential for the development of HIV (human immunodeficiency virus) resistance in HIV/HBV co-infected patients who are not also receiving highly active antiretroviral therapy (HAART) 8/16/2007 Dear Healthcare Professional Letter (Bristol-Myers Squibb)
Rosiglitazone and Risk of Heart Failure 8/14/2007 FDA Information for Healthcare Professionals
Pioglitazone and Risk of Heart Failure 8/14/2007 FDA Information for Healthcare Professionals
Omeprazole (Prilosec®) and Esomeprazole (Nexium®) and Cardiovascular Events 8/9/2007 Early Communication about an Ongoing Safety Review
Ceftriaxone (Rocephin®) and Incompatibility with Calcium Products UPDATE 8/1/2007 Dear Healthcare Professional Letter (Roche)
Ceftriaxone (Rocephin®) and Incompatibility with Calcium Products 7/5/2007 FDA Alert
Trimetrexate Glucuronate (Neutrexin®) and Drug Discontinuation 3/16/2007 Dear Healthcare Professional Letter
Ceftriaxone (Rocephin®) and Incompatibility with Calcium Products 6/1/2007 Dear Healthcare Professional Letter
Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging (marketed as Magnevist, MultiHance, Omniscan, OptiMARK, ProHance) and Risk for Nephrogenic Systemic Fibrosis 5/23/2007 FDA Alert
Rosiglitazone (Avandia®) and Cardiovascular Events 5/22/2007 Information for Healthcare Professionals
Rosiglitazone (Avandia®) and Cardiovascular Events 5/21/2007 FDA Alert
Rosiglitazone (Avandia®) and Cardiovascular Even 5/21/2007 FDA News
Antidepressant Medications and New Warnings About Suicidal Thinking, Behavior in Young Adults 5/2/2007 FDA Press Release
Ceftriaxone (Rocephin®) and Incompatibility with Calcium Products UPDATE 5/1/2007 Prescribing Information (Roche)
Look-Alike Sound-Alike Confusion Potential with Humapen Memoir® and Humira® Pen 4/5/2007 Humira Pen and HumaPen; ISMP Newsletter
Pergolide (Permax®) and Heart Valve Damage 3/29/2007 FDA Public Health Advisory
Lamivudine and Zidovudine (Combivir®) Tablets and Counterfeit Labeling 3/28/2007 Dear Pharmacy Professional Letter
Linezolid (Zyvox®) and Increased Mortality 3/16/2007 FDA Alert
Linezolid (Zyvox®) and Increased Mortality 3/16/2007 Healthcare Professional Sheet
Telithromycin (Ketek®) and Safety Issues 3/1/2007 Dear Healthcare Professional Letter
Omalizumab (Xolair®) and Anaphylactic Reactions 2/21/2007 FDA Alert
Omalizumab (Xolair®) and Anaphylactic Reactions 2/21/2007 FDA News
Omalizumab (Xolair®) and Anaphylactic Reactions 2/21/2007 Healthcare Professional Sheet
Telithromycin (Ketek®) and Serious Liver Toxicity 2/12/2007 FDA News - Label and Indication Changes
Telithromycin (Ketek®) and Serious Liver Toxicity 2/12/2007 Questions and Answers on Telithromycin
Rituximab (Rituxan®) and Progressive Multifocal Leukoencephalopathy 12/18/2006 FDA Alert
Rituximab (Rituxan®) and Progressive Multifocal Leukoencephalopathy 12/18/2006 FDA Information for Healthcare Professionals
Quinine and Unapproved Use for Leg Cramps Due to Serious Side Effects 12/11/2006 FDA News
Quinine and Unapproved Use for Leg Cramps Due to Serious Side Effects 12/11/2006 FDA Questions and Answers on Unapproved Quinine Products
Methadone (Dolophine®) and Serious Side Effects 11/27/2006 FDA Alert
Methadone (Dolophine®) and Serious Side Effects 11/27/2006 Healthcare Provider Information
Oseltamivir Phosphate (Tamiflu®) and Precaution for Neuropsychiatric Events 11/13/2006 Dear Healthcare Professional Letter
Telithromycin (Ketek®) and Serious Liver Toxicity 7/5/2006 Questions and Answers on Telithromycin
Telithromycin (Ketek®) and Serious Liver Toxicity 6/29/2006 FDA News for New Product Labeling Regarding Safety Issues
Benzocaine 2/10/2006 FDA Public Health Advisory
Benzocaine 2/8/2006 NCPS Patient Safety Alert
Telithromycin (Ketek®) and Serious Liver Toxicity 1/20/2006 FDA Public Health Advisory
Telithromycin (Ketek®) and Serious Liver Toxicity 1/20/2006 Questions and Answers on Telithromycin
Oxycontin - Diversion and Abuse 12/1/2001 VA Office of Inspector General Pharmaceutical Bulletin
return to top go